Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2024 08:00 ET | Source: Restem

RESTEM Receives FDA Orphan Drug Designation for its ULSC Program for the Treatment of Polymyositis and Dermatomyositis

CORONA, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system,...
November 18, 2024 08:00 ET | Source: Restem

RESTEM Presents Phase 1 Data of its ULSC Program in Polymyositis/Dermatomyositis at ACR Convergence 2024

- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) in patients with Polymyositis/Dermatomyositis (PM/DM),...